Mathematical model for G-CSF administration after chemotherapy.
Granulocyte-colony stimulating factor (G-CSF) is used clinically for treating chemotherapy-induced neutropenia (low neutrophil levels). Here we present a delay differential equation model for the regulation of neutrophil production that accounts for the effects of G-CSF. Using a combination of analysis and numerical simulations, we use this model to study the effects of delaying G-CSF treatment following chemotherapy for two recombinant forms of G-CSF (filgrastim and pegfilgrastim). We also examine the consequences of varying the duration of filgrastim treatment. We found that varying the starting day or the duration of G-CSF treatment can lead to different qualitative responses in the neutrophil count. These changes can be explained by the coexistence of two stable solutions in the mathematical model.
Foley
Catherine
C
Department of Mathematics and Centre for Nonlinear Dynamics, Mcgill University, 3655 Promenade Sir William Osler, Montreal, Quebec, Canada H3G 1Y6. foley@math.mcgill.ca
Mackey
Michael C
MC
D000970:Antineoplastic Agents / Q000009:adverse effects*; D004334:Drug Administration Schedule; D000069585:Filgrastim; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage*; D006801:Humans; D007958:Leukocyte Count; D008954:Models, Biological; D009503:Neutropenia / Q000097:blood / Q000139:chemically induced / Q000188:drug therapy*; D009504:Neutrophils / Q000187:drug effects / Q000473:pathology; D011092:Polyethylene Glycols; D011994:Recombinant Proteins
D000970:Antineoplastic Agents; D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor; C455861:pegfilgrastim; D011092:Polyethylene Glycols; D000069585:Filgrastim